businesspress24.com - Itonis Pharmaceuticals and Dr. Charles Hensley Placed First Purchase Order to Produce Emesyl Nausea
 

Itonis Pharmaceuticals and Dr. Charles Hensley Placed First Purchase Order to Produce Emesyl Nausea Remedy

ID: 1265918

(firmenpresse) - LAGUNA HILLS, CA -- (Marketwired) -- 09/23/13 -- Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, PhD., the inventor of the Zicam® cold remedy, are pleased to announce that the first order for Emesyl™, the company's over-the-counter homeopathic product for the relief of nausea, has been placed with Oasis Health Product, Inc.

Dr. Hensley commented, "I am pleased with the progress the company has made in getting this product ready for market."

Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.



Itonis, Inc. (the "Company") was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. For more information, please visit .



Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.









Contact:
Itonis, Inc.


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Miraculins Announces that Previously Unpublished Study Data Could Accelerate Skin Cholesterol's Use as a New Tool in U.S. Life Insurance Risk Assessment
Preventing the Spread of Antibiotic-Resistant
Bereitgestellt von Benutzer: Marketwired
Datum: 23.09.2013 - 06:00 Uhr
Sprache: Deutsch
News-ID 1265918
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

LAGUNA HILLS, CA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 128 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Itonis Pharmaceuticals and Dr. Charles Hensley Placed First Purchase Order to Produce Emesyl Nausea Remedy
"
steht unter der journalistisch-redaktionellen Verantwortung von

Itonis, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Itonis, Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 88


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.